Depot-medroxyprogesterone acetate: an update

Abstract

Objective

Depo-Provera® is a contraceptive approved by the US Food and Drug Administration (FDA) since 1992 and used worldwide by more than 90 million women.

Aim of study

Despite the fact that progestins are endogenous hormones that are secreted by the body, its excess might lead to detrimental health effects. Whether progestins as contraceptives are friends or foes is a questionable matter. In this manuscript, we drive the attention to both usage and side effects Depo-Provera.

Results

Depot-medroxyprogesterone acetate (DMPA) is a highly effective, convenient non-daily hormonal contraceptive option that has been available worldwide for many years. The experience with DMPA provides a large body of long-term data regarding the efficacy and safety of this contraceptive method; this long-term experience has established that the use of DMPA does not increase the risk of cardiovascular events, breast cancer, other gynecologic malignancy, or postmenopausal fracture; however, patients are often more concerned about the relatively immediate effects of contraceptives such as potential changes in menstrual cycle, body weight, and mood disturbances.

Conclusion

Concerns about such issues may lead to reluctance to initiate therapy or premature discontinuation. Counseling and understanding of women’s concerns and experiences using Depo-Provera is important and could help health care providers redesign counseling strategies to improve contraceptive continuation and improve patient adherence.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Camaggi CM, Strocchi E, Giovannini M (1983) Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administrations in advanced cancer patients. Cancer Chemother Pharmacol 11:19–22

    PubMed  Article  CAS  Google Scholar 

  2. 2.

    Wright CE, Antal EJ, Gillespie WR (1983) Effect of injection volume on the bioavailability of sterile Medroxyprogesterone acetate suspension. Clin Pharm 2:435–438

    PubMed  CAS  Google Scholar 

  3. 3.

    Blossey HC, Bartsch HH, Kanne D (1982) The pharmacokinetics of high-dose Medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancer. Cancer Chemother Pharmacol 8:77–81

    PubMed  Article  CAS  Google Scholar 

  4. 4.

    Speroff L, Glass RH, Kase NG (1989) Clinical gynecologic endocrinology and infertility. 4th ed. Williams & Wilkins, Baltimore, MD

    Google Scholar 

  5. 5.

    Goodman-Gilman A, Rall TW, Nies AS (1990) Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. Pergamon, New York, NY, pp 1397–1401

    Google Scholar 

  6. 6.

    Hatcher RA, Stewart F, Trussell J (1990) Contraceptive technology 1990–1992. 15th ed. Irvington, New York, NY

    Google Scholar 

  7. 7.

    Speroff L, Darney PD (1992) A clinical guide for contraception. Williams & Wilkins, Baltimore, MD

    Google Scholar 

  8. 8.

    Product Information (1998) Depo-Provera(R), medroxyprogesterone. The Upjohn Company, Kalamazoo, MI

    Google Scholar 

  9. 9.

    Product Information (1999) Premphase (R), conjugated estrogens/medroxyprogesterone acetate. Wyeth Ayerst Laboratories, Philadelphia, PA

    Google Scholar 

  10. 10.

    Di Celser K, Gruber C, Hayes C (1982) Medroxyprogesterone acetate and homozygous sickle-cell disease. Lancet 2:229–232

    Google Scholar 

  11. 11.

    Notelovitz M, Kitchens G, Ware M (1983) Combination estrogen and progestogen replacement therapy does not adversely affect coagulation. Obstet Gynecol 62:596–600

    PubMed  CAS  Google Scholar 

  12. 12.

    Roche J (1984) Steroid-induced arachnoiditis. Med J Aust 140:281–284

    PubMed  CAS  Google Scholar 

  13. 13.

    Kirkham C, Hahn PM, Van Vugt DA (1991) A randomized, double-blind, placebo-controlled, cross-over trial to asses the side effect of medroxyprogesterone acetate in hormone replacement therapy. Obstet Gynecol 78:93–97

    PubMed  CAS  Google Scholar 

  14. 14.

    Guiloff E, Ibarra-Polo A, Zanartu J (1974) Effect of contraception on lactation. Am J Obstet Gynecol 118:42–45

    PubMed  CAS  Google Scholar 

  15. 15.

    Halderman LD, Nelson AL (2002) Impact of early postpartum administration of progestin-only hormonal contraceptives compared with nonhormonal contraceptives on short-term breast-feeding patterns. Am J Obstet Gynecol 186:1250–1256

    PubMed  Article  CAS  Google Scholar 

  16. 16.

    Amatayakul K, Sivasomboon B, Thanangkul O (1980) A study of the mechanism of weight gain in medroxyprogesterone acetate users. Contraception 22:605–622

    PubMed  Article  CAS  Google Scholar 

  17. 17.

    Moore LL, Valuck R, McDougall C, Fink W (1995) A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Contraception 52:215–219

    PubMed  Article  CAS  Google Scholar 

  18. 18.

    Bahamondes L, Diaz J, Petta C, Hall P (1998) Weight variation in users of the once-a-month injectable contraceptive cyclofem. Adv Contracept 14:223–230

    Article  Google Scholar 

  19. 19.

    Kaunitz AM (1999) Long-acting injectable contraception with depot medroxyprogesterone acetate. Am J Obstet Gynecol 170:1543–1549

    Google Scholar 

  20. 20.

    Risser WL, Gefter LR, Barratt MS, Risser JM (1999) Weight change in adolescents who used hormonal contraception. Adolesc Health 24:433–436

    Article  CAS  Google Scholar 

  21. 21.

    Espey E, Steinhart J, Ogburn T, Qualls C (2000) Depo-Provera associated with weight gain in Navajo women. Contraception 62:55–58

    PubMed  Article  CAS  Google Scholar 

  22. 22.

    Bahamondes L, Del-Castillo S, Tabares G, Arce XE, Perrotti M, Petta C (2001) Comparison of weight increase in users of depot medroxyprogesterone acetate and copper IUD up to 5 years. Contraception 64:223–225

    PubMed  Article  CAS  Google Scholar 

  23. 23.

    Mangan SA, Larsen PG, Hudson S (2002) Overweight teens at increased risk for weight gain while using depot medroxyprogesteroneacetate. J Pediatr Adolesc Gynecol 15:79–82

    PubMed  Article  Google Scholar 

  24. 24.

    Shadoan MK, Anthony MS, Rankin SE, Clarkson TB, Wagner JD (2003) Effects of tibolone and conjugated equine estrogens with or without medroxyprogesterone acetate on body composition and fasting carbohydrate measures in surgically postmenopausal monkeys. Metabolism 52:1085–1089

    PubMed  Article  CAS  Google Scholar 

  25. 25.

    Mia AR, Siddiqui NI, Khan MR, Shampa SS, Rukunuzzaman, Akhter M, Kamrunnaher (2004) Effect of prolonged use of injectable hormonal contraceptives on blood pressure and body weight. Mymensingh Med J 13:30–32

    PubMed  CAS  Google Scholar 

  26. 26.

    Goldsmith NF, Johnston JO (1975) Bone mineral: effects of oral contraceptives, pregnancy, and lactation. J Bone Joint Surg Am 57:657–668

    PubMed  CAS  Google Scholar 

  27. 27.

    Cundy T, Cornish J, Roberts H, Elder H, Reid IR (1998) Spinal bone density in women using depot medroxyprogesterone contraception. Obstet Gynecol 92:569–573

    PubMed  Article  CAS  Google Scholar 

  28. 28.

    Orr-Walker BJ, Evans MC, Ames RW, Clearwater JM, Cundy T, Reid IR (1998) The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol (Oxf) 49:615–618

    Article  CAS  Google Scholar 

  29. 29.

    Scholes D, LaCroix AZ, Ott SM, Ichikawa LE, Barlow WE (1999) Bone mineral density in women using depot medroxyprogesterone acetate for contraception. Obstet Gynecol 93:233–238

    PubMed  Article  CAS  Google Scholar 

  30. 30.

    Tong OS, Tang G, Yip PS, Li B (2000) Further evaluation on long-term depot-medroxyprogesterone acetate use and bone mineral density: a longitudinal cohort study. Contraception 62:161–164

    Article  Google Scholar 

  31. 31.

    Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK (1996) Stroke in users of low-dose oral contraceptives. N Engl J Med 335:8–15

    PubMed  Article  CAS  Google Scholar 

  32. 32.

    Berenson AB, Breitkopf CR, Grady JJ, Rickert VI, Thomas A (2001) Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet Gynecol 103:899–906

    Google Scholar 

  33. 33.

    Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM (2002) Injectable hormone contraception and bone density: results from a prospective study. Epidemiology 13:581–587

    PubMed  Article  Google Scholar 

  34. 34.

    Busen NH, Britt RB, Rianon N (2003) Bone mineral density in a cohort of adolescent women using depot medroxyprogesterone acetate for one to two years. J Adolesc Health 32:257–259

    PubMed  Article  Google Scholar 

  35. 35.

    Lara-Torre E, Edwards CP, Perlman S, Hertweck SP (2004) Bone mineral density in adolescent females using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol 17:17–21

    PubMed  Article  Google Scholar 

  36. 36.

    Liu JH, Muse KN (2005) The effects of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial. Am J Obstet Gynecol 192:1316–1323

    PubMed  Article  CAS  Google Scholar 

  37. 37.

    Kaunitz AM (1996) Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. J Reprod Med 41:419–427

    PubMed  CAS  Google Scholar 

  38. 38.

    Valente PT, Schantz HD, Trabal JF (1998) Cytologic changes in cervical smears associated with prolonged use of depot-medroxyprogesterone acetate. Cancer 25:328–334

    Article  Google Scholar 

  39. 39.

    Jordan A (1994) Toxicology of depot medroxyprogesterone acetate. Contraception 49:189–201

    PubMed  Article  CAS  Google Scholar 

  40. 40.

    Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T et al (2007) Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 25:2798–2803

    PubMed  Article  CAS  Google Scholar 

  41. 41.

    Brent RL (2005) Nongenital malformations following exposure to progestational drugs: the last chapter of an erroneous allegation. Birth Defects Res A Clin Mol Teratol 73:906–918

    PubMed  Article  CAS  Google Scholar 

  42. 42.

    Eel-Gindi E, Ahmed-Nasr M (1993) Hormonal versus genetic factors in limb and heart anomalies. Cardiovasc Surg 1:381–383

    Google Scholar 

  43. 43.

    Wilkins L (1960) Masculinization of female fetus due to use of orally given progestins. JAMA 172:1028–1032

    CAS  Google Scholar 

  44. 44.

    Gal I (1967) Hormonal pregnancy tests and congenital malformation. Nature 216:83

    PubMed  Article  CAS  Google Scholar 

  45. 45.

    Aarskog D )1970) Clinical and cytogenetic studies in hypospadias. Acta Paediatr Scand (suppl 203):1–62

    Google Scholar 

  46. 46.

    Heinonen OP (1977) Cardiovascular birth defects and antenatal exposure to female sex hormones. N Engl J Med 296:67–70

    PubMed  CAS  Google Scholar 

  47. 47.

    Roberts IF, West RJ (1977) Teratogenesis and maternal progesterone. Lancet II:982

    Article  Google Scholar 

  48. 48.

    Evans ANW (1980) The ingestion by pregnant women of substances toxic to the foetus. Practitioner 224:315–319

    PubMed  CAS  Google Scholar 

  49. 49.

    Mann JR (1983) Transplacental carcinogenesis (adrenocortical carcinoma) associated with hydroxyprogesterone hexanoate. Lancet II:580

    Article  Google Scholar 

  50. 50.

    Ambani LM, Joshi NJ, Vaidya RA, Devi PK (1977) Are hormonal contraceptives teratogenic? Fertil Steril 28:791–797

    PubMed  CAS  Google Scholar 

  51. 51.

    Bracken MB, Holford TR, White C, Kelsey JL (1978) Role of oral contraception in congenital malformations of offspring. Int J Epidemiol 7:309–317

    PubMed  Article  CAS  Google Scholar 

  52. 52.

    Saksena SK, Salmonsen R, Lau IF (1979) Termination of pregnancy in the rat by RMI 12,936. Contraception 19:481–488

    PubMed  Article  CAS  Google Scholar 

  53. 53.

    Lau IF, Hoogasian J, Wong SK, Saksena SK (1980) Effects of prostaglandin F2 alpha and an antiprogestational steroid, RMI 12,936, on rat pregnancy. Prostaglandins Med 4:121–132

    PubMed  Article  CAS  Google Scholar 

  54. 54.

    Nora JJ, Nora AH, Blu J, Ingram J, Fountain A, Peterson M, Lortscher RH, Kimberling WJ (1980) Exogenous progestogen and estrogen implicated in birth defects. IARC Sci Publ, pp 169–178

  55. 55.

    Savolainen E, Saksela E, Saxen L (1981) Teratogenic hazards of oral contraceptives analyzed in a national malformation register. Am J Obstet Gynecol 1:521–524

    Google Scholar 

  56. 56.

    Starkov MV, Shashkina LF, Remezova MI (1975) A morphohistochemical study of the embryotropic action of steroids with androgenic properties. Arkh Patol 37:45–50

    PubMed  CAS  Google Scholar 

  57. 57.

    Rands PL, White RD, Carter MW, Allen SD, Bradshaw WS (1982) Indicators of developmental toxicity following prenatal administration of hormonally active compounds in the rat. I. Gestational length. Teratology 25:37–43

    PubMed  Article  CAS  Google Scholar 

  58. 58.

    Eibs HG, Spielmann H, Hagele M (1982a) Teratogenic effects of progestin treatment during the pre- and postimplantation period of mouse embryos. Teratology 22:288–289

    Google Scholar 

  59. 59.

    Eibs HG, Spielmann H, Jacob-Muller U, Klose J (1982b) Teratogenic effects of cyproterone acetate and medroxyprogesterone treatment during the pre- and postimplantation period of mouse embryos. II. Cyproterone acetate and medroxyprogesterone acetate treatment before implantation in vivo and in vitro. Teratology 25:291–299

    PubMed  Article  CAS  Google Scholar 

  60. 60.

    Kricker A, Elliott JW, Forrest JM, McCredie J (1986) Congenital limb reduction deformities and use of oral contraceptives. Am J Obstet Gynecol 155:1072–1078

    PubMed  CAS  Google Scholar 

  61. 61.

    Yovich JL, Turner SR, Draper R (1988) Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects. Teratology 38:135–144

    PubMed  Article  CAS  Google Scholar 

  62. 62.

    Yovich JL, Turner SR, Draper R (1989) Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects. Obstet Gynecol Surv 44:447–449

    Google Scholar 

  63. 63.

    Pardthaisong T, Yenchit C, Gray R (1992) The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation. Contraception 45:313–324

    PubMed  Article  CAS  Google Scholar 

  64. 64.

    Anon (1982) Pregnancy categories for prescription drugs. FDA Drug Bull 12:24–25

    Google Scholar 

  65. 65.

    Briggs MD, Hoffman SM, King LM, Olsen AS, Mohrenweiser H, Leroy JG, Mortier GR, Rimoin DL, Lachman RS, Gaines ES et al (1995) Pseudoachondroplasia and multiple epiphyseal dysplasia due to mutations in the cartilage oligomeric matrix protein gene. Nat Genet 10:330–336

    PubMed  Article  CAS  Google Scholar 

  66. 66.

    Borgatta L, Murthy A, Chuang C, Beardsley L, Burnhill MS (2002) Pregnancies diagnosed during Depo-Provera use. Contraception 66:169–172

    PubMed  Article  Google Scholar 

  67. 67.

    Wooltorton E (2005) Medroxyprogesterone acetate (Depo-Provera) and bone mineral density loss. J Ayub Med Coll Abbottabad 172:746

    Google Scholar 

  68. 68.

    FDA (2005) Depo-Provera (medroxyprogesterone acetate injectable suspension) revised product monograph, Pfizer. Available: http://www.fda.gov/medwatch/SAFETY/2004/safety04.htm#Depo (click on: November 2004—Label—Pfizer) (Accessed 8 Feb 2005)

  69. 69.

    Sannes E, Lyngset A, Nafstad I (1983) Teratogenicity and embryotoxicity of orally administered lynestrenol in rabbits. Arch Toxicol 52:23–33

    PubMed  Article  CAS  Google Scholar 

  70. 70.

    Barlow SM, Knight AF, Sullivan FM (1980) Diazepam-induced cleft palate in the mouse: the role of endogenous maternal corticosterone. Teratology 21:149–155

    PubMed  Article  CAS  Google Scholar 

  71. 71.

    Prahalada S, Hendrickx AG (1983) Embryotoxicity of Norlestrin, a combined synthetic oral contraceptive, in rhesus macaques (Macaca mulatta). Teratology 27:215–222

    PubMed  Article  CAS  Google Scholar 

  72. 72.

    Tarara R (1984) The effect of medroxyprogesterone acetate (Depo-Provera) on prenatal development in the baboon (Papio anubis): a preliminary study. Teratology 30:181–185

    PubMed  Article  CAS  Google Scholar 

  73. 73.

    Prahalada S, Carroad E, Cukierski M, Hendrickx AG (1985) Embryotoxicity of a single dose of medroxyprogesterone acetate (MPA) and maternal serum MPA concentrations in cynomolgus monkey (Macaca fascicularis). Teratology 32:421–432

    PubMed  Article  CAS  Google Scholar 

  74. 74.

    Poggel A, Hendrickx AG, Korte R, Leuschner F, Neumann BW, Prahalada S, Binkerd PE, Gunzel P (1987) Embryotoxicity of sex steroidal hormone combinations in nonhuman primates: I. Norethisterone acetate + ethinylestradiol and progesterone + estradiol benzoate (Macaca mulatta, Macaca fascicularis, and Papio cynocephalus). Teratology 35:119–127

    PubMed  Article  Google Scholar 

  75. 75.

    Carbone JP, Figurska K, Buck S, Brent RL (1990) Effect of gestational sex steroid exposure on limb development and endochondral ossification in the pregnant C57Bl/6J mouse: I. Medroxyprogesterone acetate. Teratology 42:121–130

    PubMed  Article  CAS  Google Scholar 

  76. 76.

    Carbone JP, Brent RL (1993) Genital and non genital teratogenesis of prenatal progestogen therapy: the effects of 17 alpha-hydroxyprogesterone caproate on embryonic and fetal development and endochondral ossification in the C57B1/6J mouse. Am J Obstet Gynecol 169:1292–1298

    PubMed  CAS  Google Scholar 

  77. 77.

    Jordan A (1994) Toxicology of depot medroxyprogesterone acetate. Contraception 49:189–201

    PubMed  Article  CAS  Google Scholar 

  78. 78.

    Bishun N, Mills J, Parke JV, Williams DC (1975) A cytogenetic study in women who had used oral contraceptives and in their progeny. Mutat Res 33:299–310

    PubMed  CAS  Google Scholar 

  79. 79.

    Klinger HP, Glasser M, Kava HW (1976) Contraceptives and the conceptus. I. Chromosome abnormalities of the fetus and neonate related to maternal contraceptive history. Obstet Gynecol 48:40–48

    PubMed  CAS  Google Scholar 

  80. 80.

    Muller R, Ritter C (1978) Cytogenetic studies on women during and following the use of hormonal contraceptives. Zentralbl Gynakol 51:125–129

    Google Scholar 

  81. 81.

    Tu ZH, Wang MY, Qi XD, Xu WB, Xu DH (1992) Lack of mutagenicity and teratogenicity of 16-methylene–17-alpha-acetoxy-19-norprogesterone. Zhongguo Yao Li Xue Bao 13:183–186

    PubMed  CAS  Google Scholar 

  82. 82.

    Shyama SK, Abdul Rahiman M (1993) Progestin (norethisterone)-induced genetic damage in mouse bone marrow. Mutat Res 300:215–221

    PubMed  Article  CAS  Google Scholar 

  83. 83.

    Herzog R, Leuschner J, Henning (1995) Evaluation of the mutagenicity of medroxyprogesterone acetate in vitro and in vivo. Arzneimittelforschung 45:311–314

    PubMed  CAS  Google Scholar 

  84. 84.

    Lanari C, Luthy I, Lamb CA, Fabris V, Pagano E, Helguero LA, Sanjuan N, Merani S, Molinolo AA (2001) Five novel hormone-responsive cell lines derived from murine mammary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins. Cancer Res 61:293–302

    PubMed  CAS  Google Scholar 

  85. 85.

    Giovanni B, Martelli A (2002) Are some progestins genotoxic liver carcinogens? Mutation Research 512:155–163

    Article  Google Scholar 

  86. 86.

    Kremer J, de Bruijn HW, Hindriks FR (1980) Serum high density lipoprotein cholesterol levels in women using a contraceptive injection of depot-medroxyprogesterone acetate. Contraception 22:359–367

    PubMed  Article  CAS  Google Scholar 

  87. 87.

    Crona N, Enk L, Friberg LG, Samsioe G, Silfverstolpe G (1983) Changes in apolipoprotein AI after treatment with high-dose medroxyprogesterone acetate. Gynecol Obstet Invest 18:16–20

    Article  Google Scholar 

  88. 88.

    Gronroos M, Lehtonen A (1983) Effect of high dose progestin on serum lipids. Atherosclerosis 47:101–105

    PubMed  Article  CAS  Google Scholar 

  89. 89.

    Liew DF, Ng CS, Yong YM, Ratnam SS (1985) Long-term effects of Depo-Provera on carbohydrate and lipid metabolism. Contraception 31:51–64

    PubMed  Article  CAS  Google Scholar 

  90. 90.

    Enk L, Crona N, Friberg LG, Samsioe G, Silfverstolpe G (1985) High-dose depot-medroxyprogesterone acetate—effects on the fatty acid composition of serum lecithin and cholesterol ester. Gynecol Oncol 22:317–323

    PubMed  Article  CAS  Google Scholar 

  91. 91.

    Fahraeus L, Sydsjo A, Wallentin L (1986) Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate. Fertil Steril 45:503–506

    PubMed  CAS  Google Scholar 

  92. 92.

    Wallace EM, Wu FCW (1990) Effect of medroxyprogesterone acetate and testosterone oenanthate on serum lipoproteins in man. Contraception 41:63–71

    PubMed  Article  CAS  Google Scholar 

  93. 93.

    Garza-Flores J, De la Cruz DL, Valles de Bourges V, Sanchez-Nuncio R, Martinez M, Fuziwara JL, Perez-Palacios G (1991) Long-term effects of depot-medroxyprogesterone acetate on lipoprotein metabolism. Contraception 44:61–71

    PubMed  Article  CAS  Google Scholar 

  94. 94.

    Enk L, Landgren BM, Lindberg UB, Silfverstolpe G, Crona N (1992) A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids. Horm Metab Res 24:85–89

    PubMed  CAS  Article  Google Scholar 

  95. 95.

    Kongsayreepong R, Chutivongse S, George P, Joyce S, McCone JM, Garza-Flores J, Valles de Bourges V, Cruz DL, Perez-Palacios G, Rosseneu M (1993) A multicentre comparative study of serum lipids and apolipoproteins in long-term users of DMPA and a control group of IUD users. Contraception 47:177–191

    PubMed  Article  CAS  Google Scholar 

  96. 96.

    Miller BG, Moore NW (1983) Endometrial protein secretion during early pregnancy in entire and ovariectomized ewes. J Reprod Fertil 68:137–144

    PubMed  CAS  Article  Google Scholar 

  97. 97.

    Canto de Cetina TE, Luna MO, Cetina Canto JA, Bassol S (2004) Menstrual pattern and lipid profiles during use of medroxyprogesterone acetate and estradiol cypionate and NET-EN (200 mg) as contraceptive injections. Contraception 69:115–119

    Article  CAS  Google Scholar 

  98. 98.

    Topcuoglu A, Uzun H, Aydin S, Kahraman N, Vehid S, Zeybek G, Topcuoglu D (2005) The effect of hormone replacement therapy on oxidized low density lipoprotein levels and paraoxonase activity in postmenopausal women. Tohoku J Exp Med 205:79–86

    PubMed  Article  CAS  Google Scholar 

  99. 99.

    Bursch W, Taper HS, Lauer B, Schulte-Hermann R (1985) Quantitative histological and histochemical studies on the occurrence and stages of controlled cell death (apoptosis) during regression of rat liver hyperplasia. Virchows Arch B Cell Pathol Incl Mol Pathol 50:153–166

    PubMed  Article  CAS  Google Scholar 

  100. 100.

    Tucker MJ, Kalinowski AE, Orton TC (1996) Carcinogenicity of cyproterone acetate in the mouse. Carcinogenesis,l 17:1473–1476

    Article  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Sayed Bakry.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bakry, S., Merhi, Z.O., Scalise, T.J. et al. Depot-medroxyprogesterone acetate: an update. Arch Gynecol Obstet 278, 1–12 (2008). https://doi.org/10.1007/s00404-007-0497-z

Download citation

Keywords

  • Depo-Provera
  • Risk of cardiovascular events
  • Osteoporosis
  • Gynecologic malignancy
  • Body weight gain